Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183190 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL58098 | 0.81 | GLO1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL88552 | 0.81 | GLO1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12391156 | 0.81 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL21086708 | 0.80 | KISS1R (0.32) | — | |
| SCHEMBL16861443 | 0.78 | TUBB1 (0.33) | — | |
| SCHEMBL16862667 | 0.78 | TUBB1 (0.33) | — | |
| SCHEMBL22643755 | 0.78 | TUBB1 (0.33) | — | |
| SCHEMBL5578339 | 0.78 | TUBB1 (0.33) | — | |
| SCHEMBL5578335 | 0.78 | TUBB1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666901-B2 | -[(Diethylamino)methylene]-7,11-dihydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,10-dioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; antitumor, -carcinogenic, proliferative agents; imroved antitumor activity; nontoxic; TOR (target of rapamycin) inhibitors | WYETH (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1799699-A1 | ANALOGS OF 17-HYDROXYWORTMANNIN AS PI3K INHIBITORS | Wyeth (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | WYETH (US) | 2006-06-15 | — | — | US | disclosed |
| WO-2006044453-A1 | ANALOGS OF 17-HYDROXYWORTMANNIN AS PI3K INHIBITORS | WYETH (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | STK17A, STK17B, HSD17B7 | ALDH1A1 1914/4885SMN1; SMN2 4632/4885TSHR 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.